The US Food and Drug Administra-tion has recently issued 10-15 letters on violative reminder ads for prescription drugs and is rethinking its policies on these ads, says the head of the FDA drug marketing, surveillance and enforcement branch, Kenneth Feather.
Reminder ads have got "a little out of hand," he told the Food and Drug Law Institute, and are now saying "an awful lot of things that (they) should not say." Reminder ads are used to promote the availability of approved drugs, and may give pricing information but not, says the FDA, any data about the use of the drug.
The agency is also "taking a hard look" at preapproval ads, particularly those which mention product names. Again, he said, some of these ads have "gone a little overboard, and we need to tighten up on that a little bit." No great change would be made to existing policies, but there would probably be some modifications, he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze